Klindamicin Kalceks (Clindamycin)

Clindamycin inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, blocking the translocation step of peptide chain elongation. This action stops bacterial growth (bacteriostatic) and, at higher concentrations, can be bactericidal, especially against anaerobic organisms.

The specific dose and duration of therapy are determined by the prescribing clinician based on the type and severity of infection, patient age, weight, renal and hepatic function, and local antimicrobial guidelines. No fixed regimen is provided here.

Safety data for clindamycin in pregnancy are limited, and the product is classified as pregnancy category unknown. It should be used only if the potential benefit justifies the potential risk to the fetus. Caution is also advised during breastfeeding, as the drug is excreted in milk.

To place an enquiry, visit the product page at gnhindia.com, enter the required quantity, and submit the request. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and required import documentation.

Clindamycin offers a valuable alternative to β‑lactam antibiotics, especially for patients with penicillin allergy or infections caused by anaerobic bacteria. Compared with vancomycin, it has oral bioavailability and a broader spectrum against certain anaerobes, but it lacks activity against many Gram‑negative organisms where a β‑lactam or carbapenem may be preferred.

Store the injectable solution at ambient temperature, preferably below 25 °C, in its original container. Protect it from direct light, moisture, and extreme temperature fluctuations. Do not freeze the product, and keep it out of reach of children.

Klindamicin Kalceks is supplied as a sterile injectable solution for intramuscular (IM) or intravenous (IV) administration. The route, infusion rate, and dilution are determined by the prescribing clinician based on the infection type, patient condition, and local practice standards.

The most serious adverse events include Clostridioides difficile‑associated colitis, which can be severe or fatal, severe hypersensitivity reactions such as anaphylaxis, and rare but life‑threatening skin reactions like Stevens‑Johnson syndrome or toxic epidermal necrolysis. Prompt medical attention is required if these occur.

Patients with a known hypersensitivity to clindamycin, lincomycin, or other lincosamide antibiotics should avoid this product. Caution is also advised in individuals with a history of severe colitis, hepatic impairment, or those taking interacting medications without appropriate monitoring.